Nucleic Acid Therapy Accelerator (NATA) Transforms Target Assessment with Kiin Bio's Virtual Scientist Platform

Accelerating target assessment for nucleic acid therapies through automated, evidence-driven intelligence

The Nucleic Acid Therapy Accelerator (NATA) is a UK-based translational research hub catalysing the development of nucleic acid-based therapeutics. Through interdisciplinary collaboration across academia, the NHS, industry, and the charitable sector, NATA drives high-quality science to address diseases with significant unmet medical needs.

The Challenge

Identifying the right therapeutic targets for nucleic acid-based therapies demands integration of diverse, complex data sources:

• Literature evidence on gene-disease associations

• Gene structure, variants, protein structure, and tissue expression data

• Biological and pathway databases

• Clinical trial registries

• Epidemiology and patient population insights

• Commercial intelligence and competitive landscapes

For NATA, the manual process of synthesising this information was labour-intensive, time-consuming, and difficult to scale, creating bottlenecks in their discovery pipeline.

NATA needed a solution that could deliver rapid, evidence-driven insights without compromising scientific rigor.

The Solution

NATA partnered with Kiin Bio to leverage KiinOS, our Virtual Scientist Platform, to automate and accelerate target assessment for oligonucleotide therapies.

How KiinOS Transformed Their Workflow:

Our vResearchScientist and vBusinessAnalyst Virtual Scientists enabled NATA to:

• Automate comprehensive target assessment by integrating data from literature, biological databases, clinical trials, and commercial intelligence

• Characterise candidate genes in hours instead of days, dramatically compressing research cycles

• Receive continuous intelligence updates on genes of interest, with new findings automatically contextualised to their research needs

• Scale flexibly to accommodate new targets at any stage of discovery

This end-to-end automated workflow replaced static, one-off reviews with continuously evolving intelligence, providing NATA with dynamic evidence packages for every gene under consideration.

The Results

• Speed: 90% reduction in research time, target assessments completed in hours, not days

• Scalability: Seamless expansion to new targets without resource bottlenecks

• Comprehensiveness: Actionable, cross-disciplinary insights spanning literature, databases, clinical trials, and commercial landscapes

• Continuous Intelligence: Automated updates eliminated manual re-scanning of emerging data

• Pipeline Impact: De-risked early discovery projects and strengthened prioritisation of high-value targets

• 
  

This novel approach empowered NATA to accelerate their nucleic acid therapeutics pipeline while making more efficient use of limited resources.

Kiin Bio's Virtual Scientist Platform will transform the process and time taken to evaluate targets amenable to nucleic acid therapies. What normally takes days or even weeks of fragmented manual work can now be automated and scaled. Access to continuous updates, provides us with the confidence to accelerate the development of high value targets.

Prof. Nick Lench,
Executive Director, NATA

The Impact

By partnering with Kiin Bio, NATA transformed their target assessment process from a manual, time-intensive workflow into a scalable, dynamic system that drives faster, more confident decision-making.

This collaboration demonstrates how KiinOS is reshaping drug discovery, enabling research organisations to unlock insights with unprecedented speed, precision, and adaptability.

Ready to accelerate your discovery pipeline? Contact us to learn how KiinOS can transform your research workflow.